Home Crystal structure of (E)-6-morpholino-2-(4-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one, C22H20F3NO2
Article Open Access

Crystal structure of (E)-6-morpholino-2-(4-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one, C22H20F3NO2

  • Yu Chen , Yu-Xin Pan , Rui Xu , Yu-Hao Miao , Lu Yu , Qing-Guo Meng and Gui-Ge Hou ORCID logo EMAIL logo
Published/Copyright: April 18, 2025
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 240 Issue 3

Abstract

C22H20F3NO2, monoclinic, P21/c (no. 14), a = 18.2286(3) Å, b = 15.0613(3) Å, c = 6.4904(1) Å, β = 94.082(2)°, V = 1777.40(5) Å3, Z = 4, Rgt(F) = 0.0388, wRref(F2) = 0.1082, T = 293 K.

CCDC no.: 2418287

The crystal structure is shown in Figure 1. Displacement ellipsoids are drawn at the 50 % probability level.

Table 1 contains details on crystal structure and measurement conditions. The list of the atoms including atomic coordinates and displacement parameters can be found in the cif- file attached to this article.

Table 1:

Data collection and handling.

Crystal: Clear light colourless block
Size: 0.15 × 0.12 × 0.10 mm
Wavelength: CuKα radiation (1.54178 Å)
μ: 0.96 mm−1
Diffractometer, scan mode: Rigaku, φ and ω scans
θmax, completeness: 74.4°, 100 %
N(hkl)measured, N(hkl)unique, Rint: 9161, 3516, 0.021
Criterion for Iobs, N(hkl)gt: Iobs > 2σ(Iobs), Iobs > 2σ(Iobs)(Iobs), 3,304
N(param)refined: 254
Programs: Rigaku, 1 SHELX 2 , 3

1 Source of material

According to the synthesis method in reference 4 , 5 , 6 , morphine (27.86 g, 0.32 mol) and potassium carbonate (55.4 g, 0.40 mol) were weighed into a 500 mL round-bottled flask and N,N-dimethylformamide (25.0 mL) was added to react at 313 K for 12 h. Then 6-fluoro-3,4-dihydronaphthalen-1(2H)-one (6.56 g, 0.04 mol) was added to the system at 393 K reflux reaction. Thin-Layer Chromatography (TLC, Dichloromethane:Methyl alcohol = 15:1, v:v) monitored the reaction process, and the reaction was stopped after 6 h. After the reaction system was restored to room temperature, solid-liquid separation was separated and the filter cake was washed white with dichloromethane (20.0 mL). The solvent was spun off and then separated by column chromatography with dichloromethane:methyl alcohol (30:1, v:v) as eluent to obtain the intermediate 6-morpholino-3,4-dihydronaphthalen-1 (2H)-one. The intermediate (2.31 g, 0.01 mol) and 4-(trifluoromethyl)benzaldehyde (3.48 g, 0.02 mol) were dissolved in methanol (20.0 mL) and followed by 25 % sodium hydroxide solution (10.0 mL) as catalyst at 293 K for 24 h. Then it was washed and precipitated with petroleum ether and ultrasonic with acetone for 15 min. Dichloromethane (5.0 mL) and methanol alcohol (5.0 mL) were added for recrystallization at room temperature to obtain transparent crystal of (E)-6-morpholino-2-(4-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one.

2 Experimental details

The H atoms were placed in idealized positions and treated as riding on their parent atoms, with d(C–H) = 0.97 Å (methylene), Uiso(H) = 1.2 Ueq(C), and d(C–H) = 0.93 Å (aromatic), Uiso(H) = 1.2 Ueq(C).

3 Comment

3,4–Dihydronaphthalen-1(2H)-one derivatives have been reported in many articles and are considered as a new kind anti-inflammatory, anti-tumor modifier 7 , 8 and have also been shown to be active ingredients for the prevention of Alzheimer’s disease and dementia. 9 The study found that there is an active pocket on the right side of it, 10 and small molecule drugs with different effects can be obtained by splicing different active functional groups. The introduction of benzene improves catalytic activity 11 and the electron-withdrawing group has been shown to have excellent anti-inflammatory and anti-tumor effects. 12 At the same time, nitrogen-containing heterocyclic compounds also have good biological activity and are the main pharmacophore of small molecule compounds. Morpholine fragments play a key role in the treatment of malignant tumors. 13 Therefore, we introduced morpholine and electron-absorbing group trifluoromethyl in the synthesis to further improve the activity of 3,4-dihydronaphthalen-1(2H)-one derivatives. The intermediate was obtained by nucleophilic substitution reaction with morpholine and 6-fluoro-3,4-dihydronaphthalen-1(2H)-one, and then the target compound was obtained by Claisen–Schmidt reaction with 4-(trifluoromethyl)benzaldehyde.

Single crystal structure analysis revealed that the title compound is monoclinic with only one drug molecule in the asymmetric unit (cf. Figure 1) and is consistent with previously reported compounds. 14 3,4-Dihydronaphthalone is the main pharmacophore, followed by the introduction of morpholine at C6 position and 4-(trifluoromethyl)benzaldehyde at C2 position to form α,β-unsaturated ketone. In this molecule, the bond lengths of C(1)=O(1), C(1)–C(2), C(2)–C(3) and C(3)–C(4) located on the parent nucleus are 1.2246(15) Å, 1.5030(17) Å, 1.5033(16) Å, 1.5225(16) Å. The dihedral angle between these two planes is 14.69(3)°. At the same time, double bonds can be introduced at the C2 position through Claisen–Schmidt reaction, which allows the parent nucleus to be coplanar with p-trifluorobenzyl group. The bond length between C(2)=C(11) is 1.3459(17) Å, and the torsion angle of O(1)=C(1)–C(2)=C(11) is about 1.56(18)°. It is worth noting that the bond lengths of C(18)–F(1), C(18)–F(2), C(18)–F(3) are essentially the same. They are 1.3351(17) Å, 1.3326(16) Å, 1.3365(16) Å, respectively. 15 , 16 , 17 In addition, C(19)–N(1) and C(21)–N(1) on morphin has a bond length of about 1.4726(16) Å and 1.4675(16) Å. The morphin ring adopts a “chair” configuration. 16

Corresponding author: Gui-Ge Hou, School of Pharmacy, Binzhou Medical University, Yantai, 264003, P.R. China, E-mail:

Acknowledgments

This work was supported by Shandong Laboratory Program (No. SYS202205), Shandong Provincial Natural Science Foundation (Nos. ZR2022MH159 and ZR2023MH190) and Shandong Province Science and Technology-based Small and Medium-sized Enterprises Innovation Capacity Enhancement Project (No. 2023TSGC0870).

References

1. Rigaku OD. CrysAlisPRO; Rigaku Oxford Diffraction Ltd: Yarnton, Oxfordshire, England, 2017.Search in Google Scholar

2. Sheldrick, G. M. A Short History of SHELX. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Search in Google Scholar PubMed

3. Sheldrick, G. M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Chen, Y.; Wang, J. P.; Wang, M. D.; Yu, W. X.; Cui, Y. T.; Gao, H. X.; Hou, G. G.; Ren, Y. Crystal Structure of (E)-2-(4-(1H-imidazole-1-yl) Benzylidene)-7-Fluoro-3,4-Dihydronaphthalen-1(2h)-One, C20H15FN2O. Z. Kristallogr. NCS. 2025, 240 (1), 19–21; https://doi.org/10.1515/ncrs-2024-0294.Search in Google Scholar

5. Li, X. W.; Miao, Y. H.; Ding, Y. X.; Hou, G. G. Crystal Structure of 9-Fluoro-4-(6-Methoxypyridin-2-Yl)-5,6-Dihydrobenzo [(h)]quinazolin-2-Amine, C18H15FN4O. Z. Kristallogr. NCS. 2025, 240 (1), 37–39; https://doi.org/10.1515/ncrs-2024-0330.Search in Google Scholar

6. Li, Y. L.; Meng, Q. G.; Hou, G. G.; Geng, Z. K. Crystal Structure of 2-((2-Fluoro-4-(trifluoromethyl)phenyl)(hydroxy)methyl)-7-Methoxy-3,4-Dihydronaphthalen-1((2h))-One, C19H16F4O3. Z. Kristallogr. NCS. 2023, 238, 1157–1159; https://doi.org/10.1515/ncrs-2023-0373.Search in Google Scholar

7. Barlow, J. W.; Zhang, T.; Woods, O.; Adam, J.; John, J. W. Novel Mast Cell-Stabilising Amine Derivatives of 3,4-Dihydronaphthalen-1(2h)-One and 6,7,8,9-tetrahydro-5H-Benzo[7]annulen-5-One. Med. Chem. 2011, 7 (3), 213–223; https://doi.org/10.2174/157340611795564222.Search in Google Scholar PubMed

8. Luan, M. Z.; Zhang, X. F.; Yang, Y.; Meng, Q. G.; Hou, G. G. Anti-inflammatory Activity of Fluorine-Substituted Benzo[h] Quinazoline-2-Amine Derivatives as NF-κB Inhibitors. Bioorg. Chem. 2023, 132, 106360; https://doi.org/10.1016/j.bioorg.2023.106360.Search in Google Scholar PubMed

9. Ding, Y.; Ko, M. H.; Pehar, M.; Kotch, F.; Peters, N. R.; Luo, Y.; Salamat, S. M.; Puglielli, L. Biochemical Inhibition of the Acetyltransferases ATase1 and ATase2 Reduces (β)-Secretase (BACE1) Levels and A(β) Generation. J. Biol. Chem. 2012, 287 (11), 8424–8433; https://doi.org/10.1074/jbc.m111.310136.Search in Google Scholar PubMed PubMed Central

10. Li, W. X.; Yu, L.; Chi, J. B.; Wang, J. P.; Liu, Y. J.; Wang, C. H.; Zhang, M.; Hou, G. G. Discovery of Anti-inflammatory Agents from 3,4-Dihydronaphthalene-1(2h)-One Derivatives by Inhibiting NLRP3 Inflammasome Activation. Eur. J. Med. Chem. 2024, 268, 116284; https://doi.org/10.1016/j.ejmech.2024.116284.Search in Google Scholar PubMed

11. Gao, C. L.; Hou, G. G.; Liu, J.; Ru, T.; Xu, Y. Z.; Zhao, S. Y.; Ye, H.; Zhang, L. Y.; Chen, K. X.; Guo, Y. W.; Pang, T.; Li, X. W. Synthesis and Target Identification of Benzoxepane Derivatives as Potential Anti-neuroinflammatory Agents for Ischemic Stroke. Angew. Chem., Int. Ed. 2020, 59, 2429–2439; https://doi.org/10.1002/anie.201912489.Search in Google Scholar PubMed

12. Sun, Y.; Zhou, Y. Q.; Liu, Y. K.; Zhang, H. Q.; Hou, G. G.; Meng, Q. G.; Hou, Y. Potential Anti-neuroinflammatory NF-κB Inhibitors Based on 3,4-Dihydronaphthalen-1(2h)-One Derivative. J. Enzym. Inhib. Med. Chem. 2020, 35, 1631–1640; https://doi.org/10.1080/14756366.2020.1804899.Search in Google Scholar PubMed PubMed Central

13. Luo, W. J.; Liu, Y. Q.; Qin, H.; Zhao, Z. Y.; Wang, S. Q.; He, W. M.; Tang, S. S.; Peng, J. M. Nitrogen-containing Heterocyclic Drug Products Approved by the FDA in 2023: Synthesis and Biological Activity. Eur. J. Med. Chem. 2024, 279, 116838; https://doi.org/10.1016/j.ejmech.2024.116838.Search in Google Scholar PubMed

14. Xia, D. L.; Wang, J. P.; Yu, W. X.; Wang, M. D.; Gao, H. X.; Cui, Y. T.; Hou, G. G. Crystal Structure of (E)-6,8-Dimethoxy-4-(4-morpholinobenzylidene)-3,4-dihydro-1-benzoxepin-5(2H)-one, C23H25NO5. Z. Kristallogr. NCS. 2024, 239, 1133–1136; https://doi.org/10.1515/ncrs-2024-0329.Search in Google Scholar

15. Yu, L.; Meng, Q. G.; Hou, G. G.; Liu, Y. J.; Geng, Z. K. Crystal Structure of 2-Amino-4-(2-fluoro-3-(trifluoromethyl)phenyl)-9-methoxy-1,4,5,6-tetrahydrobenzo[h]quinazolin-3-ium chloride, C20H18ClF4N3O. Z. Kristallogr. NCS. 2023, 238 (6), 1161–1163; https://doi.org/10.1515/ncrs-2023-0374.Search in Google Scholar

16. Luo, H. L.; Li, W. X.; Bai, X. Y.; Meng, Q. G.; Hou, Y. Crystal Structure of (E)-7-Fluoro-2-(4-morpholinobenzylidene)-3,4-dihydronaphthalen-1(2H)-one, C21H20FNO2. Z. Kristallogr. NCS. 2023, 238 (3), 495–497; https://doi.org/10.1515/ncrs-2023-0053.Search in Google Scholar

17. Lu, Y.; Wang, J.- P.; Wang, M.- D.; Wen-Xiao, Y.; Cui, Y.- T.; Gao, H.- X.; Liu, Y.- J.; Hou, G.-G. Crystal structure of (E)-6-(4-ethylpiperazin-1-yl)-2-(3-fluorobenzylidene)-3,4-dihydronaphthalen-1(2H)-one, C23H25FN2O. Z. Kristallogr. - New Cryst. Struct. 2024, 239, 515; https://doi.org/10.1515/ncrs-2024–0066.10.1515/ncrs-2024-0066Search in Google Scholar
Received: 2025-02-06
Accepted: 2025-03-31
Published Online: 2025-04-18
Published in Print: 2025-06-26

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of 5,5′-bis(2,4,6-trinitrophenyl)-2,2′-bi(1,3,4-oxadiazole), C16H4N10O14
  4. Crystal structure of catena-poly[(μ3-4,4′-oxydibenzoato- κ5 O,O′: O″,O‴:O‴)-bis(2,4,6-tri(3-pyridine)-1,3,5-triazine-κ1 N)cadmium(II)], C50H32CdN12O5
  5. The crystal structure of 1,4-diazepane-1,4-diium potassium trinitrate, C5H14KN5O9
  6. The crystal structure of benzyl 2,2,5,5-tetramethylthiazolidine-4-carboxylate, C15H21NO2S
  7. Crystal structure of 2-hydroxyethyl-triphenylphosphonium tetracyanidoborate, C24H20BN4OP
  8. The crystal structure of 1-methyl-3-(N-methylnitrous amide–N-methylene) imidazolidine-2,4,5-trione
  9. Crystal structure of N-((3-cyano-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-4-(2,2,2-trifluoroacetyl)-1H-pyrazol-5-yl)carbamoyl)-2,6-difluorobenzamide, C20H7Cl2F8N5O3S
  10. Crystal structure of 5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-a] isoquinolin-6(5H)-one, C20H18F2N2O
  11. The crystal structure of N′,N″-[1,2-bis(4-chlorophenyl)ethane-1,2-diylidene]bis(furan-2- carbohydrazide), C24H16Cl2N4O4
  12. Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromoantimony(III), [C25H21BrP]+[SbBr4]−
  13. Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromidoindium(III), [C25H21BrP]+[InBr4]−
  14. The crystal structure of 4-carboxy-2-oxobutan-1-aminium chloride, C5H10ClNO3
  15. Crystal structure of (4-(4-chlorophenyl)-1H-pyrrole-3-carbonyl)ferrocene, C21H16ClFeNO
  16. The crystal structure of dichlorido(η6-p-cymene)(triphenylarsine)ruthenium(II), C28H29AsCl2Ru
  17. Crystal structure of (Z)-2-hydroxy-N′-(1-(o-tolyl)ethylidene)benzohydrazide, C16H16N2O2
  18. The crystal structure of 10-(1-bromoethyl)-14-(bromomethyl)dibenzo[a, c]acridine, C24H17NBr2
  19. Synthesis and crystal structure of 6-methoxy-7-[(4-methoxyphenyl)methoxy]-2H-1-benzopyran-2-one, C18H16O5
  20. Synthesis and crystal structure of ethyl 4-((4-trifluoromethylbenzyl)amino)benzo, C17H16F3NO2
  21. The crystal structure of (Z)-2-(tert-butyl)-6-(7-(tert-butyl)-5-methylbenzo[d][1,3]oxathiol-2-ylidene)-4-methylcyclohexa-2,4-dien-1-one, C23H28O2S
  22. The crystal structure of (R)-2-aminobutanamide hydrochloride, C4H11ClN2O
  23. Crystal structure of bromido[hydridotris(3-tert-butyl-5-isopropylpyrazolyl)borato-κ3 N,N′,N″]copper(II), C30H52BBrCuN6
  24. Crystal structure of chlorido{hydridotris[3-mesityl-5-methyl-1H-pyrazol-1-yl-κN3]borato}-copper(II) dichloromethane monosolvate
  25. Crystal structure of 4-[3,5-bis(propan-2-yl)-1H-pyrazol-4-yl]pyridine, C14H19N3
  26. Crystal structure of ((4-(4-bromophenyl)-1H-pyrrol-3-yl)methyl)ferrocene, C21H16BrFeNO
  27. Crystal structure of [(4-chlorobenzyl)triphenylphosphonium] dichloridocopper(I), {[C25H21ClP]+[CuCl2]−}n
  28. The crystal structure of {Cu(2,9-diisopropyl-4,7-diphenyl-1,10-phenanthroline)[4,5-bis(diphenylphosphino)-9,9-dimethylxanthene]}+ PF6−·1.5(EtOAC)
  29. Crystal structure of 3,5-bis(t-butyl)-1H-pyrazol-4-amine, C11H21N3
  30. Crystal structure of [(2,4-dichlorobenzyl)triphenylphosphonium] trichloridocopper(II), [C25H20Cl2P]+[CuCl3]−
  31. The crystal structure of dipotassium sulfide, K2S
  32. Crystal structure of (4-(4-methoxyphenyl)-1H-pyrrole-3-carbonyl)ferrocene, C22H19FeNO2
  33. Crystal structure of (E)-6-(4-methylpiperazin-1-yl)-2-(4-(trifluoromethyl)benzylidene)-3, 4-dihydronaphthalen-1(2H)-one, C23H23F3N2O
  34. Crystal structure of (E)-6-morpholino-2-(4-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one, C22H20F3NO2
  35. Crystal structure of Ce9Ir37Ge25
  36. The crystal structure of ethyl 6-(2-nitrophenyl)imidazo[2,1-b]thiazole-3-carboxylate, C14H11N3O4S
  37. Crystal structure of (4-(4-isopropylphenyl)-1H-pyrrol-3-yl)(ferrocenyl)methanone, C24H23FeNO
  38. Crystal structure of bis(methylammonium) tetrathiotungstate(VI), (CH3NH3)2[WS4]
  39. Crystal structure of 6,11-dihydro-12H-benzo[e]indeno[1,2-b]oxepin-12-one, C17H12O2
  40. Crystal structure of 3-[(4-phenylpiperidin-1-yl)methyl]-5-(thiophen-2-yl)-2,3-dihydro-1,3,4- oxadiazole-2-thione, C18H19N3OS2
  41. Crystal structure of N-isopropyl-1,8-naphthalimide C15H13NO2
  42. TiNiSi-type EuPdBi
  43. Crystal structure of 1-(p-tolylphenyl)-4-(2-thienoyl)-3-methyl-1H-pyrazol-5-ol, C16H14N2O2S
  44. The crystal structure of 3-(3-carboxypropyl)-2-nitro-1H-pyrrole 1-oxide, C7H9N3O5
  45. The crystal structure of tetraaqua-bis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k2O:N)-tetrakis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k1N)trizinc(II) hexahydrate C36H52N18O32Zn3
  46. The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 4-hydroxy-3,5-dimethoxybenzoate monohydrate, C25H30FN3O9
  47. Crystal structure of bis(DL-1-carboxy-2-(1H-indol-3-yl)ethan-1-aminium) oxalate — acetic acid (1/2)
  48. Crystal structure of methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate, C12H15NO4S
  49. The crystal structure of actarit, C10H11NO3
  50. The crystal structure of bicyclol, C19H18O9
  51. The crystal structure of topiroxostat, C13H8N6
  52. Crystal structure of 2,2-dichloro-N-methyl-N-(4-p-tolylthiazol-2-yl)acetamide, C13H12Cl2N2OS
  53. Crystal structure of 4-(trifluoromethyl)-7-coumarinyl trifluoromethanesulfonate C11H4F6O5S
  54. Crystal structure of (1,4,7,10,13,16-hexaoxacyclooctadecane-κ6O6)-((Z)-N,N′-bis(2-(dimethylamino)phenyl)carbamimidato-κ1N)potassium(I)
  55. Crystal structure of (Z)-2-(5-((4-(dimethylamino)naphthalen-1-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, C18H16N2O3S2
  56. Crystal structure of (4-fluorobenzyl)triphenylphosphonium bromide, C25H21BrFP
  57. The crystal structure of dichlorido-[6-(pyridin-2-yl)phenanthridine-κ2N, N′]zinc(II)-chloroform (1/1), C19H13N2ZnCl5
  58. Crystal structure of (E)-(3-(2,4-dichlorophenyl)acryloyl)ferrocene, C19H14Cl2FeO
  59. The crystal structure of (E)-7-chloro-1-cyclopropyl-6-fluoro-3-((2-hydroxybenzylidene)amino)quinolin-4(1H)-one, C19H14ClFN2O2
  60. Crystal structure of 2-bromo-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13BrFNO4S2
  61. Crystal structure of 2-chloro-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13ClFNO4S2
  62. Crystal structure of 5-(2,2-difluoropropyl)-5-methyl-6-oxo-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline-3-carbonitrile, C20H15F2N3O
https://doi.org/10.1515/ncrs-2025-0067
Creative Commons
BY 4.0

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of 5,5′-bis(2,4,6-trinitrophenyl)-2,2′-bi(1,3,4-oxadiazole), C16H4N10O14
  4. Crystal structure of catena-poly[(μ3-4,4′-oxydibenzoato- κ5 O,O′: O″,O‴:O‴)-bis(2,4,6-tri(3-pyridine)-1,3,5-triazine-κ1 N)cadmium(II)], C50H32CdN12O5
  5. The crystal structure of 1,4-diazepane-1,4-diium potassium trinitrate, C5H14KN5O9
  6. The crystal structure of benzyl 2,2,5,5-tetramethylthiazolidine-4-carboxylate, C15H21NO2S
  7. Crystal structure of 2-hydroxyethyl-triphenylphosphonium tetracyanidoborate, C24H20BN4OP
  8. The crystal structure of 1-methyl-3-(N-methylnitrous amide–N-methylene) imidazolidine-2,4,5-trione
  9. Crystal structure of N-((3-cyano-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-4-(2,2,2-trifluoroacetyl)-1H-pyrazol-5-yl)carbamoyl)-2,6-difluorobenzamide, C20H7Cl2F8N5O3S
  10. Crystal structure of 5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-a] isoquinolin-6(5H)-one, C20H18F2N2O
  11. The crystal structure of N′,N″-[1,2-bis(4-chlorophenyl)ethane-1,2-diylidene]bis(furan-2- carbohydrazide), C24H16Cl2N4O4
  12. Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromoantimony(III), [C25H21BrP]+[SbBr4]−
  13. Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromidoindium(III), [C25H21BrP]+[InBr4]−
  14. The crystal structure of 4-carboxy-2-oxobutan-1-aminium chloride, C5H10ClNO3
  15. Crystal structure of (4-(4-chlorophenyl)-1H-pyrrole-3-carbonyl)ferrocene, C21H16ClFeNO
  16. The crystal structure of dichlorido(η6-p-cymene)(triphenylarsine)ruthenium(II), C28H29AsCl2Ru
  17. Crystal structure of (Z)-2-hydroxy-N′-(1-(o-tolyl)ethylidene)benzohydrazide, C16H16N2O2
  18. The crystal structure of 10-(1-bromoethyl)-14-(bromomethyl)dibenzo[a, c]acridine, C24H17NBr2
  19. Synthesis and crystal structure of 6-methoxy-7-[(4-methoxyphenyl)methoxy]-2H-1-benzopyran-2-one, C18H16O5
  20. Synthesis and crystal structure of ethyl 4-((4-trifluoromethylbenzyl)amino)benzo, C17H16F3NO2
  21. The crystal structure of (Z)-2-(tert-butyl)-6-(7-(tert-butyl)-5-methylbenzo[d][1,3]oxathiol-2-ylidene)-4-methylcyclohexa-2,4-dien-1-one, C23H28O2S
  22. The crystal structure of (R)-2-aminobutanamide hydrochloride, C4H11ClN2O
  23. Crystal structure of bromido[hydridotris(3-tert-butyl-5-isopropylpyrazolyl)borato-κ3 N,N′,N″]copper(II), C30H52BBrCuN6
  24. Crystal structure of chlorido{hydridotris[3-mesityl-5-methyl-1H-pyrazol-1-yl-κN3]borato}-copper(II) dichloromethane monosolvate
  25. Crystal structure of 4-[3,5-bis(propan-2-yl)-1H-pyrazol-4-yl]pyridine, C14H19N3
  26. Crystal structure of ((4-(4-bromophenyl)-1H-pyrrol-3-yl)methyl)ferrocene, C21H16BrFeNO
  27. Crystal structure of [(4-chlorobenzyl)triphenylphosphonium] dichloridocopper(I), {[C25H21ClP]+[CuCl2]−}n
  28. The crystal structure of {Cu(2,9-diisopropyl-4,7-diphenyl-1,10-phenanthroline)[4,5-bis(diphenylphosphino)-9,9-dimethylxanthene]}+ PF6−·1.5(EtOAC)
  29. Crystal structure of 3,5-bis(t-butyl)-1H-pyrazol-4-amine, C11H21N3
  30. Crystal structure of [(2,4-dichlorobenzyl)triphenylphosphonium] trichloridocopper(II), [C25H20Cl2P]+[CuCl3]−
  31. The crystal structure of dipotassium sulfide, K2S
  32. Crystal structure of (4-(4-methoxyphenyl)-1H-pyrrole-3-carbonyl)ferrocene, C22H19FeNO2
  33. Crystal structure of (E)-6-(4-methylpiperazin-1-yl)-2-(4-(trifluoromethyl)benzylidene)-3, 4-dihydronaphthalen-1(2H)-one, C23H23F3N2O
  34. Crystal structure of (E)-6-morpholino-2-(4-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one, C22H20F3NO2
  35. Crystal structure of Ce9Ir37Ge25
  36. The crystal structure of ethyl 6-(2-nitrophenyl)imidazo[2,1-b]thiazole-3-carboxylate, C14H11N3O4S
  37. Crystal structure of (4-(4-isopropylphenyl)-1H-pyrrol-3-yl)(ferrocenyl)methanone, C24H23FeNO
  38. Crystal structure of bis(methylammonium) tetrathiotungstate(VI), (CH3NH3)2[WS4]
  39. Crystal structure of 6,11-dihydro-12H-benzo[e]indeno[1,2-b]oxepin-12-one, C17H12O2
  40. Crystal structure of 3-[(4-phenylpiperidin-1-yl)methyl]-5-(thiophen-2-yl)-2,3-dihydro-1,3,4- oxadiazole-2-thione, C18H19N3OS2
  41. Crystal structure of N-isopropyl-1,8-naphthalimide C15H13NO2
  42. TiNiSi-type EuPdBi
  43. Crystal structure of 1-(p-tolylphenyl)-4-(2-thienoyl)-3-methyl-1H-pyrazol-5-ol, C16H14N2O2S
  44. The crystal structure of 3-(3-carboxypropyl)-2-nitro-1H-pyrrole 1-oxide, C7H9N3O5
  45. The crystal structure of tetraaqua-bis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k2O:N)-tetrakis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k1N)trizinc(II) hexahydrate C36H52N18O32Zn3
  46. The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 4-hydroxy-3,5-dimethoxybenzoate monohydrate, C25H30FN3O9
  47. Crystal structure of bis(DL-1-carboxy-2-(1H-indol-3-yl)ethan-1-aminium) oxalate — acetic acid (1/2)
  48. Crystal structure of methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate, C12H15NO4S
  49. The crystal structure of actarit, C10H11NO3
  50. The crystal structure of bicyclol, C19H18O9
  51. The crystal structure of topiroxostat, C13H8N6
  52. Crystal structure of 2,2-dichloro-N-methyl-N-(4-p-tolylthiazol-2-yl)acetamide, C13H12Cl2N2OS
  53. Crystal structure of 4-(trifluoromethyl)-7-coumarinyl trifluoromethanesulfonate C11H4F6O5S
  54. Crystal structure of (1,4,7,10,13,16-hexaoxacyclooctadecane-κ6O6)-((Z)-N,N′-bis(2-(dimethylamino)phenyl)carbamimidato-κ1N)potassium(I)
  55. Crystal structure of (Z)-2-(5-((4-(dimethylamino)naphthalen-1-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, C18H16N2O3S2
  56. Crystal structure of (4-fluorobenzyl)triphenylphosphonium bromide, C25H21BrFP
  57. The crystal structure of dichlorido-[6-(pyridin-2-yl)phenanthridine-κ2N, N′]zinc(II)-chloroform (1/1), C19H13N2ZnCl5
  58. Crystal structure of (E)-(3-(2,4-dichlorophenyl)acryloyl)ferrocene, C19H14Cl2FeO
  59. The crystal structure of (E)-7-chloro-1-cyclopropyl-6-fluoro-3-((2-hydroxybenzylidene)amino)quinolin-4(1H)-one, C19H14ClFN2O2
  60. Crystal structure of 2-bromo-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13BrFNO4S2
  61. Crystal structure of 2-chloro-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13ClFNO4S2
  62. Crystal structure of 5-(2,2-difluoropropyl)-5-methyl-6-oxo-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline-3-carbonitrile, C20H15F2N3O
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 17.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2025-0067/html
Scroll to top button